Observational studies analyzed like randomized experiments: An application to postmenopausal hormone therapy and coronary heart disease

Epidemiology

Volumn 19, Issue 6, 2008, Pages 766-779

  Hernán, Miguel A ^a,b   Alonso, Alvaro ^c   Logan, Roger ^a   Grodstein, Francine ^a,d   Michels, Karin B ^a,d,e   Willett, Walter C ^a,d   Manson, Joann E ^a,d,e   Robins, James M ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; CONJUGATED ESTROGEN;

ADULT; ARTICLE; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MENOPAUSE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; CARDIOVASCULAR DISEASE; ESTROGEN THERAPY; HEALTH SURVEY; LONGITUDINAL STUDY; METHODOLOGY; MIDDLE AGED; OBSERVATION; RANDOMIZED CONTROLLED TRIAL; RISK; STATISTICAL ANALYSIS; TIME;

CARDIOVASCULAR DISEASES; DATA INTERPRETATION, STATISTICAL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HEALTH SURVEYS; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; OBSERVATION; ODDS RATIO; PROGESTINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 61449524241     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/EDE.0b013e3181875e61     Document Type: Article

References (30)

1. Ioannidis JP, Haidich AB, Pappa M, et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA. 2001;286:821-830.
2. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342:1878-1886.
3. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342:1887-1892.
4. Grodstein F, Stampfer M, Manson J, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease [Erratum in: N Engl J Med. 1996;335:1406]. N Engl J Med. 1996;335:45 3-461.
5. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intem Med. 2000; 133:933-941.
6. Varas-Lorenzo C, García-Rodríguez LA, Perez-Gutthann S, et al. Hormone replacement therapy and incidence of acute myocardial infarction. Circulation. 2000; 101:2572-2578.
7. The Women's Health Initiative Study Group.Design of the women's health initiative clinical trial and observational study. Control Clin Trials. 1998;19:61-109.
8. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523-534.
9. Prentice RL, Pettinger M, Anderson GL. Statistical issues arising in the Women's Health Initiative. Biometrics. 2005;61:899-911.
10. Hernán MA, Robins JM, Garcia Rodriguez LA. In discussion of: Prentice RL, Pettinger M, Anderson GL. Statistical issues arising in the Women's Health Initiative. Biometrics. 2005;61:922-930.
11. Stampfer MJ, Hu FB, Manson JE, et al. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med. 2000;343:16-22.
12. Robins JM. The analysis of randomized and non-randomized AIDS treatment trials using a new approach to causal inference in longitudinal studies. In: Sechrest L, Freeman H, Mulley A, eds. Health Services Research Methodology: A Focus on AIDS: NCHRS, US. Washington, DC: Public Health Service;1989:l 13-159.
13. Mendelsohn ME, Karas RH. Hormone replacement therapy and the young at heart. N Engl J Med. 2007;356:2639-2641.
14. Mark SD, Robins JM. A method for the analysis of randomized trials with compliance information: an application to the Multiple Risk Factor Intervention Trial. Control Clin Trials. 1993;14:79-97.
15. Cole SR, Chu H. Effect of acyclovir on herpetic ocular recurrence using a structural nested model. Comtemp Clin Trials. 2005;26:300-310.
16. Hernán MA, Hernández-Díaz S, Robins JM. A structural approach to selection bias. Epidemiology. 2004; 15:615-625.
17. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Women's Health. 2006; 15:35-44.
18. Manson JE, Bassuk SS. Invited commentary: hormone therapy and risk of coronary heart disease why renew the focus on the early years of menopause? Am J Epidemiol. 2007;166:511-517.
19. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med. 2003;348:645-650.
20. Harman SM, Brinton EA, Cedars M, et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric. 2005;8:3-12.
21. Prentice RL, Langer RD, Stefanick ML, et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the women's health initiative clinical trial. Am J Epidemiol. 2005;162:404-414.
22. Robins JM. A new approach to causal inference in mortality studies with a sustained exposure period - Application to the healthy worker survivor effect [published errata appear in Math Model. 1987;14:917-921]. Math Model. 1986;7:1393-1512.
23. Robins JM. Addendum to "A new approach to causal inference in mortality studies with a sustained exposure period - application to the healthy worker survivor effect" [published errata appear in Comput Math Appl. 1989:18;477]. Comput Math Appl. 1987; 14:923-945.
24. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915-920.
25. Alonso A, Garcia Rodriguez LA, Logroscino G, et al. Gout and risk of Parkinson's disease: a prospective study. Neurology. 2007;69:1696-1970.
26. Connely M, Richardson M, Platt R. Prevalence and duration of postmenopausal hormone replacement therapy use in a managed care organization. J Gen Intem Med. 2000;15:542-50.
27. Robins JM, Rotnitzky A, Vansteelandt S. In discussion of: Frangakis CE, Rubin DB, An M, MacKenzie E. "Principal stratification designs to estimate input data missing due to death". Biometrics. 2007;63: 650-662.
28. Robins JM. Structural nested failure time models. In: Armitage P, Colton T, eds. Survival Analysis. The Encyclopedia of Biostatistics. Chichester, UK: John Wiley and Sons; 1998:4372-4389.
29. Hernán MA, Cole SR, Margolick J, et al. Structural accelerated failure time models for survival analysis in studies with time-varying treatments. Pharmacoepidemiol Drug Saf. 2005;14:477-491.
30. Robins JM, Blevins D, Ritter G, et al. G-estimation of the effect of prophylaxis therapy for Pneumocystis carinii pneumonia on the survival of AIDS patients [published errata appear in Epidemiology. 1993:4; 189]. Epidemiology. 1992;3:319-336.